Navigating PROTACs in Cancer Therapy: Advancements, Challenges, and Future Horizons
Food Science & Nutrition · 2025-02 · 13 (2)
DOI: 10.1002/fsn3.70011 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Food Science & Nutrition, online erschienen am 01.02.2025. Verfasst von Saooda Ibrahim und 8 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Molecular Biology and Biotechnology The University of Lahore Lahore Pakistan. Die Arbeit wurde bisher 28-mal zitiert (Crossref) und nennt 170 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Proteolysis Targeting Chimeras (PROTACs) have revolutionized cancer therapy by offering a selective and innovative approach to degrade key oncogenic proteins associated with various malignancies. These hybrid molecules exploit the ubiquitin‐proteasome system, facilitating the degradation of target proteins through an event‐driven mechanism, thereby overcoming drug resistance and enhancing selectivity. With diverse targets including androgen receptors, BTK, estrogen receptors, BET proteins, and BRAF, PROTACs offer a versatile strategy for personalized cancer treatment. Advantages of PROTACs over traditional small molecule inhibitors include their ability to operate at lower concentrations, catalyzing the degradation of multiple proteins of interest with reduced cytotoxicity. Notably, PROTACs address challenges associated with traditionally “undruggable” targets, expanding the therapeutic landscape of cancer therapy. Ongoing preclinical and clinical studies highlight the transformative potential of PROTACs, with promising results in prostate, breast, lung, melanoma, and colorectal cancers. Despite their potential, challenges persist in optimizing physicochemical properties and enhancing bioavailability. Further research is needed to refine PROTAC design and address complexities in molecule development. Nevertheless, the development of oral androgen receptor PROTACs represents a significant milestone, demonstrating the feasibility and efficacy of this innovative therapeutic approach. This review provides a comprehensive overview of PROTACs in cancer therapy, emphasizing their mechanism of action, advantages, and challenges. As PROTAC research progresses, continued exploration in both preclinical and clinical settings will be crucial to unlocking their full therapeutic potential and shaping the future of personalized cancer treatment.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Institute of Molecular Biology and Biotechnology The University of Lahore Lahore Pakistan.
- Centre for Applied Molecular Biology University of the Punjab Lahore Pakistan.
- Department of Chemistry University of Swabi Swabi Khyber Pakhtunkhwa Pakistan.
- Department of Medical Biosciences College of Veterinary Medicine, Qassim University Buraydah Saudi Arabia.
- Department of Pathology College of Medicine, Qassim University Buraydah Saudi Arabia.
- College of Education, Seiyun University Seiyun Hadhramawt Yemen.
ORCID-Profile: Zubair Ahmad, Mohammed Mansour Quradha
Zitieren
APA
Ibrahim, S., Umer Khan, M., Khurram, I., Rehman, R., Rauf, A., Ahmad, Z., Aljohani, A. S. M., Al Abdulmonem, W., & Quradha, M. M. (2025). Navigating PROTACs in Cancer Therapy: Advancements, Challenges, and Future Horizons. Food Science & Nutrition, 13(2). https://doi.org/10.1002/fsn3.70011
Vancouver
Ibrahim S, Umer Khan M, Khurram I, Rehman R, Rauf A, Ahmad Z, et al. Navigating PROTACs in Cancer Therapy: Advancements, Challenges, and Future Horizons. Food Science & Nutrition. 2025;13(2). doi:10.1002/fsn3.70011
BibTeX
@article{Ibrahim2025,
author = {Ibrahim, Saooda and Umer Khan, Muhammad and Khurram, Iqra and Rehman, Raima and Rauf, Abdur and Ahmad, Zubair and Aljohani, Abdullah S M and Al Abdulmonem, Waleed and Quradha, Mohammed Mansour},
title = {Navigating PROTACs in Cancer Therapy: Advancements, Challenges, and Future Horizons},
journal = {Food Science & Nutrition},
year = {2025},
volume = {13},
number = {2},
doi = {10.1002/fsn3.70011}
}
EUVIMED